Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes
The company posted results of a completed Phase 3 study that enrolled 617 participants with heart failure with preserved ejection fraction and type 2 diabetes, comparing semaglutide 2.4 mg once-weekly to a dummy medicine. The trial began on June 15 2021 and reached primary completion on October 11 2023.
Primary source
ClinicalTrials.gov results record, November 2, 2026
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Read the source: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation